Klearmind evaluates patients seeking care for treatment-resistant psychiatric symptoms and selected chronic pain conditions. Ketamine is not FDA-approved for psychiatric disorders or chronic pain. Whether off-label treatment is medically appropriate is determined individually following a physician evaluation.

There is no single treatment schedule that is appropriate for every patient. Some IV treatment plans may involve an initial series followed by reassessment. Oral programs have separately defined treatment and reevaluation requirements. The physician determines the recommended schedule based on the patient's clinical needs and response.

Ketamine has established medical uses as an anesthetic, but treatment still involves risks and is not appropriate for every patient. Klearmind evaluates relevant medical conditions, medications, contraindications, and risk factors before recommending treatment. Monitoring requirements depend on the treatment route and individual care plan.

Patients generally remain conscious, although they may experience sedation, dissociation, changes in perception, or other effects. Clinical staff monitor patients during the infusion and recovery period.

No. Secure-text clinical support is available from 6:00 a.m. to 8:00 p.m. Pacific Time. Klearmind does not provide on-call emergency services through secure text. Call 911, call or text 988, or go to the nearest emergency department during a medical or psychiatric emergency.

Ketamine affects several signaling systems in the brain, including pathways involving glutamate and NMDA receptors. Researchers continue to study how these effects may relate to mood, pain processing, and neuroplasticity. The exact response varies among individuals, and the proposed mechanism does not guarantee clinical improvement.

Ketamine is an FDA-approved anesthetic that has been used in medical settings for decades. Ketamine may also be prescribed or administered off-label for certain psychiatric and pain conditions. "Off-label" means the medication is being used for a condition or in a manner that has not been specifically approved by the FDA.

No. Klearmind does not offer intramuscular ketamine.

No. Klearmind does not offer nasal ketamine or Spravato. Spravato is an FDA-approved intranasal esketamine product and is different from racemic ketamine.

When prescribed, compounded oral ketamine is sent by the dispensing pharmacy to the patient's verified California address. Klearmind does not ship or dispense the medication.

No. Ketamine is not FDA-approved for the treatment of psychiatric disorders or chronic pain. A physician may determine that off-label treatment is medically appropriate for an individual patient after evaluating the potential benefits, risks, and alternatives.

Klearmind offers three distinct programs: (1) in-clinic IV ketamine; (2) oral ketamine-assisted psychotherapy at a participating therapist's office; (3) physician-directed at-home oral ketamine.

No. Compounded oral ketamine is not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.

No. Do not drive, operate machinery, drink alcohol or make important decisions for at least 24 hours after treatment. A responsible adult must take you home. Follow all individualized discharge instructions provided by the clinical team.